Other languages AbbVie Inc. BOERSE MUENCHEN

Equities

Real-time BOERSE MUENCHEN Other stock markets 03:52:32 2024-06-27 EDT			5-day change	1st Jan Change
159.6 ^EUR	-0.93%		+1.33%	+15.33%

01:05am	Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	CI
01:03am	U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	CI

Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	07:05pm
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	07:03pm
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	06-25
US FDA declines to approve AbbVie's Parkinson's disease therapy	06-25
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	06-25
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	06-21
AI: de toekomstperspectieven	06-21
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	06-20
US FDA proposes to remove switching study requirement for biosimilars	06-20
AbbVie Inc. Announces Board of Directors Changes	06-20
KI: Die Zukunftsaussichten	06-19
Prospettive future dell'intelligenza artificiale	06-19
AbbVie : approbation de la FDA dans la colite ulcéreuse	06-19
U.S. FDA Approves Skyrizi® (Risankizumab-Rzaa) for Ulcerative Colitis, Expanding Abbvie's Portfolio Across Inflammatory Bowel Disease	06-18
Perspectivas futuras de la IA	06-18
Les perspectives futures sur l'IA	06-17
AbbVie inks immune disorder drug licensing deal with China's FutureGen	06-13
AbbVie, FutureGen to Develop Potential Inflammatory Bowel Disease Treatment	06-13
3 Top-Picks: Auf medizinische KI setzen	06-13
Drie bedrijven om in te zetten op medische AI	06-11

No results for this search